EF Hutton Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert maintains a Buy rating on Anavex Life Sciences (NASDAQ:AVXL) with a $46 price target.
July 29, 2024 | 11:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert maintains a Buy rating on Anavex Life Sciences with a $46 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $46 price target by a reputable analyst suggests positive sentiment and confidence in Anavex Life Sciences' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100